Pak. j. life soc. Sci. (2024), 22(1): 3535-3546 E-ISSN: 2221-7630;P-ISSN: 1727-4915

Pakistan Journal of Life and Social Sciences
www.pjlss.edu.pk

https://doi.org/10.57239/PJLSS-2024-22.1.00258

RESEARCH ARTICLE

Relevance of Pro-BNB Biomarker with Left Ventricular Ejection Fraction in Coronary Artery Disease (CAD) Patients

Ola Muslim Alhussainy[1*], Dr. Haider Abd Jabbar ALammar[2], Dr. Aqeel Raheem Al-Barqawee[2]

[1, 2] Section of Medical Biochemistry, College of Medicine, University of AL – Qadisiyah, Iraq

ARTICLE INFO

Received: Apr 24, 2024

Accepted: Jun 13, 2024

Keywords

B-type natriuretic peptide (BNP)
Coronary artery disease (CAD)
ELISA

***Corresponding Author:**

olamuslim23@gmail.com

ABSTRACT

The relationship between newly discovered biomarkers Regarding the fraction of left ventricle ejection in individuals suffering from coronary artery disease (CAD).Coronary artery disease is one of the major non-communicable diseases in the world. Coronary artery damage can be caused by a number of important risk factors, such as smoking, diabetes mellitus, dyslipidemia, and hypertension (1). When compared to other plasma neurohormones, B-type natriuretic peptide (BNP) and its amino-terminal congeners differ. Studies reveal that, compared to symptomatic examination, changes in plasma BNP levels during treatment for acutely decompensated heart failure offer a more potent predictive indication of the chance of survival or recurrent decompensation.(1). This observation necessitates a randomized controlled study where aggression is determined by alterations in peptide levels. The length of in-patient treatment to determine if this indicator can enhance the outcomes of acute in-patient heart failure management. When following up on heart failure cohorts over an extended period of time, plasma BNP or NT-proBNP is a highly effective independent predictor of death and morbidity. Furthermore, it seems to be a reliable indicator of a positive reaction when beta blocker is added to anti-heart failure medication. When changing therapy for heart failure based on serial measures of NT-proBNP, as opposed to altering therapy based on independent clinical judgment, better results are expectedResearching of new biomarkers such as B-type natriuretic peptide (BNP). Associated Patients suffering from coronary artery disease (CAD) with left ventricular ejection fraction. B-type natriuretic peptide (BNP) levels in the serum were determined using the ELISA technique. Associated using the left ventricular ejection fraction when suffering from coronary heart disease)CAD Patients. Serum urea, creatinine, and RBS are measured using colorimetric and fully automated methods. Between individuals with coronary artery disease)CAD Patients and the healthy group, Pro-BNP, serum creatinine, urea, and RBS all differ statistically significantly. Individuals with coronary artery disease had significantly greater amounts of Pro-BNP and, which are diagnostic markers.

INTRODUCTION

The relationship between newly discovered biomarkers and coronary artery disease patients' left ventricular ejection fraction (CAD) Coronary artery disease is a major non-communicable disease

with a global impact. issue. There are several important risk factors that can lead to coronary artery disease, including hypertension., dyslipidemia, diabetes mellitus and smoking cigarettes (2).

Despite comprehensive documentation and guidelines highlighting the prescription of medication for secondary prevention, there was a documented underutilization of these medications, resulting in Many coronary artery disease patients do not achieve the secondary preventive therapy goal.(3) .

There are no studies evaluating the association between In patients with coronary microvascular disease and obstructive coronary artery disease, low density lipoprotein, B-type natriuretic peptide, Troponin-I, coronary flow reserve, and left ventricular ejection fraction are measured. Investigating the relationships between left ventricular ejection fraction and growth differention factor 15, B-type natriuretic peptide, and coronary flow reserve can help identify the variables that affect left ventricular ejection fraction, our investigation used a prospective clinical observational methodology.(4).

Therefore, even while treating comorbidities may delay or prevent the onset of HFpEF, it may not be enough therapy for many people. A substantial risk to the public's health, HFrEF is linked to high rates of morbidity and death. Significant scientific progress in the treatment of HFrEF has occurred in recent decades, and this presents a unique chance to alter the disease's natural path. The latest developments include SGLT2 inhibitors, Vericiguat and transcatheter mitral valve replacement are two additional neurohormonal treatments that progressively improve prognosis. Five-year survival rates for patients hospitalized with HFrEF are 25%, suggesting that the disease's morbidity and mortality rates remain very high.

A complicated neurohormonal response to increasing cardiac failure raises the levels of many plasma hormones in the blood. Greater correlation exists between cardiac shape and function, as well as cardiovascular prognosis, and increases changes the plasma concentrations of the amino-terminal congeners of B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and than there is with variations in other plasma neurohormones. Studies indicate that, compared to symptomatic assessment, A more powerful predictive indicator of the likelihood of survival or recurring decompensation is provided by variations in plasma BNP levels during the course of treatment for acutely decompensated heart failure. (1). This observation necessitates a randomized controlled study where aggression is determined by alterations in peptide levels. The length of in-patient treatment to determine if this indicator can enhance the outcomes of acute in-patient heart failure management. When following up on heart failure cohorts over an extended period of time, plasma BNP or NT-proBNP is a highly effective independent predictor of death and morbidity. Furthermore, it seems to be a reliable indicator of a positive reaction when beta blocker is added to anti-heart failure medication. When changing therapy for heart failure based on serial measures of NT-proBNP, as opposed to altering therapy based on independent clinical judgment, better results are expected.(5)

There is a negative correlation between A favorable connection has been seen between brain natriuretic peptide (BNP) and plasma atrial natriuretic peptide (ANP) levels and left ventricular ejection fraction (1-3). Analyses of heart health are more closely correlated with the plasma concentrations of BNP and amino-terminal pro-B-type natriuretic peptide (NT-proBNP). illness than are ANP or other circulating neurohumoral markers of cardiac illness. structure and function as well as cardiovascular prognosis 5-7. Consequently, BNP or NT-proBNP measures made in conjunction with Conventional clinical evaluation can help with serial treatment modification and the choice of whether to begin taking medicine to prevent heart failure. There is a dearth of data despite the wealth of studies demonstrating the connection between cardiac function, prognosis, and plasma BNP and/or NT-proBNP in a variety of cardiovascular illnesses, from acute coronary syndromes to established heart failure. on how useful single or many plasma NT-proBNP testing are for making treatment decisions. Cheng and partners (6)

In those who would BNP levels evidently increased by at least 30% in those who died within 30 days after discharge, while the NYHA class either remained same or saw a little reduction. As a result, modifications in plasma B-typeChanges in symptoms as determined by NYHA class were not as good a predictor of the 30-day results as natriuretic peptide concentrations during several days of intense therapy. Type natriuretic peptides and anti-failure medications(6).

According to neurohormonal sub-studies from important randomised controlled trials with converting enzyme inhibitors for heart failure, the benefit of starting such therapy may be predicted by plasma neurohormonal status(7).

When converting enzyme inhibition was first tested in patients with severe heart failure Ten pre-randomization measures of plasma atrial natriuretic peptide, angiotensin II, norepinephrine, renin activity, and aldosterone were all indicated (8).

An increased likelihood of benefit from enalapril introduction was predicted by angiotensin II, aldosterone, renin activity, plasma atrial natriuretic peptide, and the sum of these measurements. Subsequent reports from the V-HeFT 11 ValHeFT 7 and SAVE 12 investigations typically confirmed these conclusions. However, neurohormonal sub-studies in randomised controlled trials of heart failure treatment were conducted prior to the beta blocker medication trials. did not assess either plasma BNP or NT-proBNP.(9)

were started. Neurohormonal findings from The outcomes of the carvedilol-based ANZ Heart Failure Trial were made public by the Heart Failure Group of Australia and New Zealand. Blood was taken for a panel of neurohormones in this investigation, which included 415 people with ejection fractions and proven ischemic heart disease. in addition to standard therapy with converting enzyme inhibitors and loop diuretics. of less than 45% before they were randomly assigned to receive carvedilol or a placebo.

A decrease The overall clinical outcome was included in the composite end point, which included hospital admission and death. Regardless of treatment assignment, both BNP and NT-proBNP levels prior to randomization were linked to positive results. During the trial's post-randomization phase, elevated levels of either protein were linked to a two-fold higher risk of adverse events, like heart failure readmission. Additionally, it was noted that both peptides could independently predict a positive response to carvedilol Recent, as-yet-unpublished findings from the COPERNICUS trial in severe heart failure point to a similar pattern, with carvedilol administration providing a higher absolute benefit in the patient subgroup with the highest NT-proBNP concentrations.(1, 9) (2, 10) (2, 10),

The predictive value of BNP has been confirmed by reports from the ValHeFT trial, which compared the effects of ACE inhibitor plus valsartan or placebo in people who have a left ventricular ejection fraction of less than 40%, or congestive heart failure. The trial discovered that successive quartiles of plasma BNP levels were linked to an incremental increase in mortality over the trial's duration 7. When compared to plasma norepinephrine, BNP demonstrated a considerably higher discriminating power. It is unknown at this time whether plasma BNP indicated more benefit from valsartan added to an ACE inhibitor.(10)

Patients with an ejection fraction of ≤40% and recent decompensated heart failure in inpatient or outpatient settings were eligible to participate in the experiment. Patients were randomized to receive treatment based on a clinical algorithm that was thoroughly applied and based on the Framingham criteria for heart failure diagnosis, or on serial measurement of NT-proBNP(11). Following baseline studies Patients who met the clinical criteria used to evaluate cardiac compensation or whose plasma NT-proBNP level dropped below the target level were monitored every three months. In the event that these goals were not reached, therapy was increased gradually in accordance with a pre-established protocol, with follow-up assessments and therapy increments

happening every 10–14 days. In the hormone-guided group, mean plasma NT-proBNP levels decreased, but not in the clinically treated group. With a total of 19 cardiovascular events as opposed to 54, the heart failure group's chance of dying or experiencing a first heart failure event was significantly lower. An examination of many variables that takes into account variations age, NYHA class, initial NT-proBNP, left ventricular ejection fraction, and converting enzyme inhibitor dosage.(12)



Figure 1The Kaplan–Meier event curves show a noteworthy decrease in events in the group whose therapy was modified based on repeated measurements of plasma NT-proBNP. These curves show the time to first heart failure event or death. (Taken from with permission from The NT-proBNP-guided group exhibited a significantly significant difference in systolic blood pressure and frusemide dosage across treatment groups (P<0.001). The researchers came to the conclusion that, in comparison to intensive clinically directed treatment, treatment for It indicated that heart failure guided by NT-proBNP levels prevented cardiovascular events., and this called for additional research. The Christchurch group then went on to start a second experiment with a bigger patient population that included a wider range of age, co-morbidity, and left ventricular function in addition to a more advanced medication strategy. (13)

Under the BNP Assisted Treatment To LEssen Serial CARdiac REadmissions and Death trial, or "BATTLESCARRED," all patients who satisfy the Framingham criteria for heart failure over the age of 18 are admitted., whether or not they have a decreased ejection fraction. More than 200 patients have been enrolled thus far. Given the rising incidence of this dangerous illness and the requirement to address a wider range of dysfunction, the use of NT-proBNP or BNP for heart failure management seems justified.(13). Furthermore, the intricacy of therapy is growing as several medicines have been proven efficacious in randomised controlled studies. As time goes on, a growing number of heart failure patients will require different levels of clinical skill for diagnosis and management. As a result, an objective indicator to support A prescription for the greatest medication available is necessary. At the moment, the best choice for this function is plasma measurements of BNP or NT-proBNP.(5)

2.MATERIALS AND METHODS .

Study design :

Diagnosis of coronary artery disease made by both clinically and by laboratory testing and in The Specialized Center For Surgery and Cardiac Catheterization in Diwanyah.

Samples and other data were obtained from participants in the study, which included both healthy individuals and sick.

Laboratory testing were carried out by the lab division of The Specialized Center For Surgery and Cardiac Catheterization in Diwanyah and the medical biochemistry department of the College of Medicine at the University of Al-Qadisiyah.

Ninety individuals participated in the study between September 2023 and January 2024 (for the collection of specimens), divided into two groups.

From Nassiria Teaching Hospital, G1 45 patients with chronic renal illness were selected after their clinical and laboratory diagnoses were verified. G2: 45 people in good health who do not have any illnesses. They were confirmed following discussions with others and completion of the required laboratory tests.

Inclusion Criteria

The samples were divided into two groups : (1) patient group (2) healthy group, The first group were divided into two groups based on medical diagnosis Angina and myocardia infraction.

Ethical considerations

This study, conducted at The Specialized Center For Surgery and Cardiac Catheterization in Diwanyah, in accordance with University of AL-Qadisiyah, College of Medicine criteria, was approved by the Clinical Research Ethics.

2.2- Blood sample collecting

Each patient had five milliliters of blood drawn from their vein; one milliliter was placed in a gel and sodium citrate test tube for use in pro-BNP detection and other biochemistry analyses. A serum sample was obtained by centrifuging blood specimens in gel tubes at 3000 ×g for 10 minutes. After that, the sample was kept in three separate Eppendorf tubes in the freezer at -20 C until the study was required.

2.3- Detection of serum pro-BNB and, Urea , Creatinine and Random blood sugar.

Pro-BNP serum levels were determined using the ELISA method.

A spectrophotometer was used to measure the following:, creatinine, RBS, ,and blood urea.

2.4- statistical analysis

The correlations between serum pro-BNP levels and inflammatory parameters of patients with coronary artery disease were shown in tables (3-7). The present results show non-significant correlation between pro-BNP levels and all inflammatory parameters.

Table (3-7): Correlation between serum pro-BNP level and inflammatory parameters.

Characteristic	***pro-BNP level***	
	r	***P***
RBS	-0.194	0.155
Urea	0.022	0.872
Creatinine	0.032	0.816
EF	0.023	0.867

r: correlation coefficient



Frequency distribution of pro-BNP level according to gender of patients with coronary artery disease

Table (3-6) showed the effect of gender on pro-BNP level in patients with coronary artery disease. The results as shown in table (3-6) revealed that there was non-significant effect of gender on pro-BNP level. The higher mean value of pro-BNP has been observed in male as compared to female in patients with coronary artery disease, but showed no statistically significant differences among both gender.

Table (3-6): The levels of serum pro-BNP in patients having coronary artery disease divided according to male & female

Parameters	**Male**	**Female**	***P***
pro-BNP levels			
Mean± SD	**21.00 ± 4.31**	**18.09 ± 3.52**	**0.299 † NS**
Range	7.16 ± 47.38	7.99 ± 37.91	

n: number of cases; **SD**: standard deviation; †: independent samples t-test; NS: non- significant at $P > 0.05$.

3.4.1.3 Correlation between serum pro-BNP levels and biochemical parameters.

The correlations between serum pro-BNP levels and inflammatory parameters of patients with coronary artery disease were shown in tables (3-7). The present results show non-significant correlation between pro-BNP levels and all inflammatory parameters.

Table (3-7): Correlation between serum pro-BNP level and inflammatory parameters.

Characteristic	***pro-BNP level***	
	r	***P***
RBS	-0.194	0.155
Urea	0.022	0.872
Creatinine	0.032	0.816
EF	0.023	0.867

r: correlation coefficient.

3. RESULTS

Results of biochemical markers

The comparison of biochemical parameters in patients with coronary artery disease and healthy control subject has been carried out and the results were demonstrated in table (3-3). Mean levels of Random Blood Sugar (RBS) were 158.25 ± 18.66 and 102.97 ± 9.05, in patients with coronary artery disease and healthy control subject respectively; the level was higher in patients group in comparison with healthy control subject but the difference was highly significant (P < 0.001).

Regarding the mean levels of blood urea, the present results show the mean levels of blood urea in patients with coronary artery disease was slightly non-significant higher than the mean levels of blood urea in healthy control subject, 32.87 ± 8.25 versus 31.69 ± 3.77 respectively, (P= 0.284). Also the mean levels of serum Creatinine in patients with coronary artery disease was slightly non-significant higher than the mean levels of serum Creatinine in healthy control subject, 0.72 ± 0.21 versus 0.68 ± 0.13 respectively, (P= 0.229).

Table(3-3): Mean levels of biochemical parameters in patients with coronary artery disease and healthy control subject

	Cases –control comparison		***P***
	Patients ***n* = 55**	**Healthy control** ***n* = 71**	
Random Blood Sugar (RBS) mg/dl			
Mean± SD	**158.25 ± 18.66**	**102.97 ± 9.05**	**< 0.001** † **HS**
Range	79.00 -547.00	87.00-126.00	
Blood Urea mg/dl			
Mean± SD	**32.87 ± 8.25**	**31.69 ± 3.77**	**0.284** † **NS**
Range	15.00 -57.00	22.00-40.00	
Serum Creatinine mg/dl			
Mean ± SD	**0.72 ± 0.21**	**0.68 ± 0.13**	**0.229** † **NS**
Range	0.30 -1.20	0.40-0.90	

n: number of cases; **SD**: standard deviation; †: independent samples t-test; HS: Highly significant at P ≤ 0.001; NS: non-significant at P > 0.05



Figure (3-3): The means level of Random Blood Sugar in patients and control groups



Figure (3-4): The means level of blood urea in patients and control groups



Figure (3-5): The means level of Serum Creatinine in patients and control groups

DISCUSSIONS

Better biomarkers are needed, as our analysis makes clear, to help cardiologists concentrate on individuals with CAD who have intricate and distinct pathophysiological pathways [27]. blood pressure, ejection, creatinine, serum urea, and proteinuria Many other conventional markers are insensitive, and placing undue reliance on these results may result in protracted delays before useful treatments may be put into place [28]. While several of the biomarkers under study have demonstrated substantial promise, more validation in a larger and more diversified population is required before being applied in clinical practice. Of those studied, pro-BNP showed the greatest promise as a biomarker of the advancement of coronary artery disease (CAD) and the comparative left ventricular ejection fraction in the disease. sickness Patient blood samples are currently being examined and verified. However, it is unlikely that a single marker will fit the criteria for predicting the development of CAD given the near difficulty of precisely capturing the nuances of all the underlying pathophysiological processes involved. A small panel of biomarkers is more likely to produce the best findings for the carefully targeted CAD group [29]. In addition, prior to being converted into clinical [30]. Despite the fact that improvements in sample preparation and analysis techniques, proteomics, and metabolomic technologies have significantly increased biomarker discovery productivity and efficiency [31].

The arterial walls become damaged by high blood pressure. Damage to the arteries may increase their susceptibility to plaque accumulation, which may result in a blockage or decreased blood flow.

A heart attack or stroke may result from a blockage that happens close to the heart or brain, respectively.

In line with the CDCTcorroded Source Eight in ten persons who have a first stroke and seven out of ten who suffer a first heart attack also have. An abrupt stoppage of blood supply to a portion of the heart is known as a heart attack, or myocardial infarction Trusted Source. This usually results from an obstruction that stops blood flow normally, but supply and demand imbalances can also cause it. That portion of the heart muscle may start to die if the blood flow does not return to normal.

Heart failure—also known as congestive heart failure Trusted Source—occurs when the heart cannot adequately pump blood throughout the body. This could be because of the.

The ability to identify Over the past ten years, numerous biomarkers in blood and serum have been identified, which has made it possible to determine left ventricular ejection fraction in coronary artery disease. Before their ejection fraction drops, patients suffer from chronic injury (tubular) and early renal impairment. These indicators may need to meet a number of characteristics in order to be useful in therapeutic settings. They should enable early detection of coronary artery disease. Most markers that are used to identify CAD early require prospective testing in large populations. It would likely be necessary to use a mix of markers, such as tubular enzymes, pro-BNP, and GADF15, to maximize sensitivity and specificity for CAD. Early therapeutic and preventive treatments may ultimately come from their use. However, as of right now, no clinical trials exist.

ACKNOWLEDGMENT

The Clinical Biochemistry Branch of the University of AL Qadisiyah's College of Medicine offered the study facilities, and the authors are grateful to the entire staff of The Specialized Center for Cardiac Surgery and Catheterization in Diwaniyah for their support.

REFERENCES

[1] R. A. De Boer et al., "Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction," JAMA Cardiol, vol. 3, no. 3, 2018, doi: 10.1001/jamacardio.2017.4987.

[2] "Correction: Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort (Open Heart (2018) 5 (e000782) DOI: 10.1136/openheart-2018-000782)," Open Heart, vol. 5, no. 2. 2018. doi: 10.1136/openhrt-2018-000782corr1.

[3] M. A. Pfeffer, A. M. Shah, and B. A. Borlaug, "Heart Failure with Preserved Ejection Fraction in Perspective," Circulation Research, vol. 124, no. 11. 2019. doi: 10.1161/CIRCRESAHA.119.313572.

[4] M. M. Redfield, "Heart Failure with Preserved Ejection Fraction," New England Journal of Medicine, vol. 375, no. 19, pp. 1868–1877, Nov. 2016, doi: 10.1056/NEJMcp1511175.

[5] S. M. Dunlay, V. L. Roger, and M. M. Redfield, "Epidemiology of heart failure with preserved ejection fraction," Nature Reviews Cardiology, vol. 14, no. 10. 2017. doi: 10.1038/nrcardio.2017.65.

[6] L. van Heerebeek and W. J. Paulus, "Understanding heart failure with preserved ejection fraction: where are we today?," Netherlands Heart Journal, vol. 24, no. 4, pp. 227–236, Apr. 2016, doi: 10.1007/s12471-016-0810-1.

[7] K. Khalid et al., "Correlation of Coronary Artery Disease and Left Ventricular Hypertrophy," Cureus, 2021, doi: 10.7759/cureus.17550.

[8] G. C. Siontis et al., "Impact of left ventricular function on clinical outcomes among patients with coronary artery disease," Eur J Prev Cardiol, vol. 26, no. 12, pp. 1273–1284, Aug. 2019, doi: 10.1177/2047487319841939.

[9] J. and T. J. and T. Y. Shao Chunli and Wang, "Coronary Artery Disease: From Mechanism to Clinical Practice," in Coronary Artery Disease: Therapeutics and Drug Discovery, M. Wang, Ed., Singapore: Springer Singapore, 2020, pp. 1–36. doi: 10.1007/978-981-15-2517-9_1.

[10] S. P. Murphy, N. E. Ibrahim, and J. L. Januzzi, "Heart Failure With Reduced Ejection Fraction," JAMA, vol. 324, no. 5, p. 488, Aug. 2020, doi: 10.1001/jama.2020.10262.

[11] B. A. Borlaug, "Evaluation and management of heart failure with preserved ejection fraction," Nat Rev Cardiol, vol. 17, no. 9, pp. 559–573, Sep. 2020, doi: 10.1038/s41569-020-0363-2.

[12] G. Savarese, D. Stolfo, G. Sinagra, and L. H. Lund, "Heart failure with mid-range or mildly reduced ejection fraction," Nat Rev Cardiol, vol. 19, no. 2, pp. 100–116, Feb. 2022, doi: 10.1038/s41569-021-00605-5.

[13] S. D. Anker et al., "Empagliflozin in Heart Failure with a Preserved Ejection Fraction," New England Journal of Medicine, vol. 385, no. 16, pp. 1451–1461, Oct. 2021, doi: 10.1056/NEJMoa2107038.

[14] M. Richards and R. W. Troughton, "NT-proBNP in heart failure: therapy decisions and monitoring," Eur J Heart Fail, vol. 6, no. 3, pp. 351–354, 2004, doi: https://doi.org/10.1016/j.ejheart.2004.01.003.

[15] L. Gao et al., "Prognostic value of NT-proBNP in patients with severe COVID-19," Respir Res, vol. 21, no. 1, p. 83, Dec. 2020, doi: 10.1186/s12931-020-01352-w.

[16] R. A. Lewis, C. Durrington, R. Condliffe, and D. G. Kiely, "BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?," European Respiratory Review, vol. 29, no. 156, p. 200009, Jun. 2020, doi: 10.1183/16000617.0009-2020.

[17] A. Groenewegen, F. H. Rutten, A. Mosterd, and A. W. Hoes, "Epidemiology of heart failure," Eur J Heart Fail, vol. 22, no. 8, pp. 1342–1356, Aug. 2020, doi: 10.1002/ejhf.1858.

[18] M. V. B. Malachias et al., "NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus," J Am Heart Assoc, vol. 9, no. 19, p. e017462, 2020, doi: 10.1161/JAHA.120.017462.

[19] R. Rørth et al., "Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction," Circ Heart Fail, vol. 13, no. 2, p. e006541, 2020, doi: 10.1161/CIRCHEARTFAILURE.119.006541.

[20] Z. Cao, Y. Jia, and B. Zhu, "BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine," International Journal of Molecular Sciences, vol. 20, no. 8. 2019. doi: 10.3390/ijms20081820.

[21] S. Silva, S. Fatumo, and D. Nitsch, "Mendelian randomization studies on coronary artery disease: a systematic review and meta-analysis," Syst Rev, vol. 13, no. 1, p. 29, Jan. 2024, doi: 10.1186/s13643-023-02442-8.

[22] F. F. Darche et al., "Comparative accuracy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients," ESC Heart Fail, vol. 4, no. 3, pp. 232–240, Aug. 2017, doi: 10.1002/ehf2.12150.

[23] M. M. Redfield, "Heart Failure with Preserved Ejection Fraction," New England Journal of Medicine, vol. 375, no. 19, pp. 1868–1877, Nov. 2016, doi: 10.1056/NEJMcp1511175.

[24] M. W. Bloom et al., "Heart failure with reduced ejection fraction," Nat Rev Dis Primers, vol. 3, no. 1, p. 17058, Aug. 2017, doi: 10.1038/nrdp.2017.58.

[25] T. H. Marwick, "Ejection Fraction Pros and Cons," J Am Coll Cardiol, vol. 72, no. 19, pp. 2360–2379, 2018, doi: 10.1016/j.jacc.2018.08.2162.

[26] B. R. Pagliaro, F. Cannata, G. G. Stefanini, and L. Bolognese, "Myocardial ischemia and coronary disease in heart failure," Heart Fail Rev, vol. 25, no. 1, pp. 53–65, Jan. 2020, doi: 10.1007/s10741-019-09831-z.

[27] Y. T. Lagerros, A. Grotta, S. Freyland, D. Grannas, and D. P. Andersson, "Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors," J Am Coll Cardiol, vol. 83, no. 3, pp. 417–426, 2024, doi: 10.1016/j.jacc.2023.10.041.

[28] W. K. Ly, C. Mueller, T. Breidthardt, K. Laule-Kilian, M. Christ, and A. P. Perruchoud, "The integration of BNP and NT-proBNP into clinical medicine Summary."

[29] H. Agrawal, H. H. K. Choy, J. Liu, M. Auyoung, and M. A. Albert, "Coronary Artery Disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 40, no. 7. Lippincott Williams and Wilkins, pp. E185–E192, Jul. 01, 2020. doi: 10.1161/ATVBAHA.120.313608.

[30] C.-I. Marta et al., "A Comparative Analysis of NT-proBNP Levels in Pregnant Women and the Impact of SARS-CoV-2 Infection: Influence on Birth Outcome," Diseases, vol. 12, no. 1, p. 10, Dec. 2023, doi: 10.3390/diseases12010010.

[31] U. Islam, M. Sabbah, B. T. Özbek, J. M. Madsen, J. T. Lønborg, and T. Engstrøm, "Prognostic differences between physiology-guided percutaneous coronary intervention and optimal medical therapy in coronary artery disease: A systematic review and meta-analysis," American Heart Journal Plus: Cardiology Research and Practice, vol. 38, p. 100362, 2024, doi: https://doi.org/10.1016/j.ahjo.2024.100362.

[32] X. Dai, "Genetics of coronary artery disease and myocardial infarction," World J Cardiol, vol. 8, no. 1, p. 1, 2016, doi: 10.4330/wjc.v8.i1.1.

[33] O. Oz and A. Gonel, "Analytical Interference with Contrast Agents in Genetic Test Result for Thrombophilia," Lett Drug Des Discov, vol. 21, no. 4, pp. 823–827, Mar. 2024, doi: 10.2174/1570180820666230105164237.

[34] S. Desmedt, V. Desmedt, L. De Vos, J. R. Delanghe, R. Speeckaert, and M. M. Speeckaert, "Growth differentiation factor 15: A novel biomarker with high clinical potential," Crit Rev Clin Lab Sci, vol. 56, no. 5, pp. 333–350, Jul. 2019, doi: 10.1080/10408363.2019.1615034.

[35] K. C. Wollert, T. Kempf, and L. Wallentin, "Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease," Clin Chem, vol. 63, no. 1, pp. 140–151, Jan. 2017, doi: 10.1373/clinchem.2016.255174.

1. Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Failure. 2020;13(2):e006541.

2. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. European journal of heart failure. 2020;22(8):1342-56.

3. Gong FF, Jelinek MV, Castro JM, Coller JM, McGrady M, Boffa U, et al. Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. Open Heart. 2018;5(2):e000782.

4. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2017;14(10):591-602.

5. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. International journal of molecular sciences. 2019;20(8):1820.

6. Marwick TH. Ejection fraction pros and cons: JACC state-of-the-art review. Journal of the American College of Cardiology. 2018;72(19):2360-79.

7. Pagliaro BR, Cannata F, Stefanini GG, Bolognese L. Myocardial ischemia and coronary disease in heart failure. Heart Failure Reviews. 2020;25(1):53-65.

8. Trolle Lagerros Y, Grotta A, Freyland S, Grannas D, Andersson DP. Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors. Journal of the American College of Cardiology. 2024;83(3):417-26.

9. Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP. The integration of BNP and NT-proBNP into clinical medicine. Swiss medical weekly. 2007;137(1-2):4-12.

10. Gao L, Jiang D, Wen X-s, Cheng X-c, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respiratory research. 2020;21:1-7.

11. Islam U, Sabbah M, Özbek B, Madsen J, Lønborg J, Engstrøm T. Prognostic differences between physiology-guided percutaneous coronary intervention and optimal medical therapy in coronary artery disease: A systematic review and meta-analysis. American Heart Journal Plus: Cardiology Research and Practice. 2024:100362.

12. Dai X, Wiernek S, Evans JP, Runge MS. Genetics of coronary artery disease and myocardial infarction. World journal of cardiology. 2016;8(1):1.

13. Oz O, Gonel A. Analytical Interference with Contrast Agents in Genetic Test Result for Thrombophilia. Letters in Drug Design & Discovery. 2024;21(4):823-7.